Market Place
Sourcing Support
Belite Bio Reports Q4 and Full Year 2024 Results and Update
17 Mar 2025 //
GLOBENEWSWIRE
Belite Bio Annual Report Form 20-F Available on Company Website
17 Mar 2025 //
GLOBENEWSWIRE
Belite Bio Webcast on March 17, 2025 for 2024 Financials
11 Mar 2025 //
GLOBENEWSWIRE
Belite Bio To Join Leerink Partners Global Healthcare Conference
04 Mar 2025 //
GLOBENEWSWIRE
Belite’s Ph 3 Trial Shows Tinlarebant Benefits In Stargardt Disease
27 Feb 2025 //
GLOBENEWSWIRE
Belite Bio Announces Registered Direct Offering of $15 Million
05 Feb 2025 //
GLOBENEWSWIRE
Belite Bio Reports Q3 2024 Financial Results & Corporate Update
12 Nov 2024 //
GLOBENEWSWIRE
Belite Bio to Host Webcast on Nov 12, Q3 2024 Financial Results
05 Nov 2024 //
GLOBENEWSWIRE
Belite Bio Announces US$28.75M Gross Proceeds from Warrants
03 Nov 2024 //
GLOBENEWSWIRE
Belite Bio to Present at American Academy of Ophthalmology
14 Oct 2024 //
GLOBENEWSWIRE
Belite Bio To Participate In Maxim Group 2024 Healthcare Summit
08 Oct 2024 //
GLOBENEWSWIRE
Belite Bio Announces Doses First Patient In DRAGON II Trial
10 Sep 2024 //
GLOBENEWSWIRE
Belite Bio to Participate in Three Upcoming Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Belite Bio Appoints Hendrik P. N. Scholl, MD, MA, As Chief Medical Officer
01 Sep 2024 //
GLOBENEWSWIRE
Belite Bio Reports Q2 2024 Results And Corporate Update
09 Aug 2024 //
GLOBENEWSWIRE
Belite Bio To Present At H.C. Wainwright Ophthalmology Conference
08 Aug 2024 //
GLOBENEWSWIRE
Belite Bio to Host Webcast to Discuss Second Quarter 2024 Financial Results
05 Aug 2024 //
GLOBENEWSWIRE
Belite Bio to Present at the JonesHealthcare Seaside Summit
08 Jul 2024 //
GLOBENEWSWIRE
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant
12 Jun 2024 //
GLOBENEWSWIRE
Belite Bio To Participate In Benchmark Healthcare Investor Conference
14 May 2024 //
GLOBENEWSWIRE
Belite Bio To Participate In H.C. Wainwright BioConnect Investor Conference
13 May 2024 //
GLOBENEWSWIRE
Belite Bio Q1 2024 Financials, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Belite Bio Q1 2024 Results Webcast On May 14
08 May 2024 //
GLOBENEWSWIRE
Belite Bio KOL Webinar On STGD1, GA And Tinlarebant
06 May 2024 //
GLOBENEWSWIRE
Belite Presents More Tinlarebant Phase 2 Stargardt Data At ARVO
06 May 2024 //
GLOBENEWSWIRE
Belite Bio To Present At ARVO 2024 Annual Meeting
01 May 2024 //
GLOBENEWSWIRE
Belite Bio Announces $25 Million Registered Direct Offering
25 Apr 2024 //
GLOBENEWSWIRE
Belite Bio Announces PMDA Subof Tinlarebant for Stargardt Disease Trial in Japan
22 Mar 2024 //
GLOBENEWSWIRE
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results
11 Mar 2024 //
GLOBENEWSWIRE
Belite Bio Announces Availability of Annual Report on Form 20-F
11 Mar 2024 //
GLOBENEWSWIRE
Belite Bio to Discuss Fourth Quarter and Full Year 2024 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
04 Mar 2024 //
GLOBENEWSWIRE
Belite Bio to Present at the Oppenheimer 34th Annual Life Sciences Conference
07 Feb 2024 //
GLOBENEWSWIRE
Belite Bio to Participate in the Benchmark Company™s Investor Conference
30 Nov 2023 //
GLOBENEWSWIRE
Belite Bio to Participate in the BTIG Ophthalmology Day
20 Nov 2023 //
GLOBENEWSWIRE
Belite Bio Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Belite Bio to Host Webcast to Discuss Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant
06 Nov 2023 //
GLOBENEWSWIRE
Belite Bio Announces Presentation at the American Academy of Ophthalmology
27 Oct 2023 //
GLOBENEWSWIRE
Belite Bio Reports Q2 2023 Operational Highlights and Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Belite Bio to Host Webcast to Discuss Second Quarter 2023 Financial Results
04 Aug 2023 //
GLOBENEWSWIRE
Belite Doses First Subject in Phase 3 Trial Evaluating Oral Tinlarebant for GA
27 Jul 2023 //
GLOBENEWSWIRE
Belite Completes Enrollment in Phase 3 DRAGON Trial Evaluating Tinlarebant
24 Jul 2023 //
GLOBENEWSWIRE
Belite Bio Announces Proposed Underwritten Public Offering
30 May 2023 //
GLOBENEWSWIRE
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering
30 May 2023 //
GLOBENEWSWIRE
Belite Bio to Host Webcast on May 11, 2023 to Discuss 1Q 2023 Financial Results
10 May 2023 //
GLOBENEWSWIRE
Belite Bio Reports 1Q 2023 Operational Highlights and Financial Results
10 May 2023 //
GLOBENEWSWIRE
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression Childhood
04 May 2023 //
GLOBENEWSWIRE
Belite Bio Presented 18-Month Interim Data from a 24-Month Ph2 Tinlarebant
25 Apr 2023 //
GLOBENEWSWIRE
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant
11 Apr 2023 //
GLOBENEWSWIRE
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year FYR
31 Mar 2023 //
GLOBENEWSWIRE
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
31 Mar 2023 //
GLOBENEWSWIRE
Belite Bio finalises Tinlarebant Phase III trial design to treat dry AMD
21 Nov 2022 //
CLINICALTRIALSARENA
Belite Bio Finalizes Ph3 Trial Plans for Advanced Dry AMD with Tinlarebant
18 Nov 2022 //
GLOBENEWSWIRE
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022
20 Oct 2022 //
GLOBENEWSWIRE
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study
01 Oct 2022 //
GLOBENEWSWIRE
Belite Bio Announces Late-Breaking Presentation at the American Academy
23 Sep 2022 //
GLOBENEWSWIRE
Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
16 Sep 2022 //
GLOBENEWSWIRE
Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008
22 Aug 2022 //
GLOBENEWSWIRE
Belite Bio Reports First Half 2022 Operational Highlights and Financial Results
10 Aug 2022 //
GLOBENEWSWIRE
